Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 17/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.71 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31620029 | 1.00 | MPO (0.71) | MPOHTR2ATRPM8GPR84HTR1A | |
| SCHEMBL5583919 | 0.90 | MPO (0.72) | MPOHTR2ATRPM8GPR84HTR1A | |
| SCHEMBL5584045 | 0.89 | MPO (0.73) | MPOHTR2ATRPM8GPR84HTR1A | |
| SCHEMBL7710633 | 0.86 | HTR2A (0.71) | MPOHTR2ATRPM8GPR84HTR1A | |
| SCHEMBL517983 | 0.83 | MPO (0.73) | MPOHTR2ATRPM8GPR84HTR1A | |
| SCHEMBL7845587 | 0.83 | MPO (0.71) | MPOHTR2ATRPM8GPR84HTR1A | |
| SCHEMBL7871799 | 0.83 | MPO (0.71) | MPOHTR2ATRPM8GPR84HTR1A | |
| SCHEMBL8261020 | 0.83 | MPO (0.71) | MPOHTR2ATRPM8GPR84HTR1A | |
| SCHEMBL387663 | 0.83 | MPO (1.00) | MPOHTR2ATRPM8GPR84HTR1A | |
| SCHEMBL2122451 | 0.83 | MPO (0.75) | MPOHTR2ATRPM8GPR84HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988377-B2 | Small molecule inducers of GDNF as potential new therapeutics for neuropsychiatric disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-06-05 | — | — | US | disclosed |
| US-9303023-B2 | Pyrazole and imidazole derivatives useful as orexin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-04-05 | — | — | US | disclosed |
| EP-2675801-B1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-20150056699-A1 | SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-02-26 | — | — | US | disclosed |
| US-20130324579-A1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-05 | — | — | US | disclosed |
| WO-2013028999-A1 | SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-02-28 | — | — | WO | disclosed |
| EP-2044016-B1 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | GRUENENTHAL GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-8138187-B2 | Substituted heteroaryl derivatives | GRUENENTHAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | GRUNENTHAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| CN-101516844-A | 4-heteroaryl substituted 1-aminocyclohexane-1-and cyclohexene-1-derivatives having activity on opioid receptor systems | GRUENENTHAL GMBH (DE) | 2009-08-26 | — | — | CN | disclosed |
| US-20010051627-A1 | Substituted 2-(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)- 4(3H)-azaquinazolinones | CLARK ROBIN DOUGLAS (US) | 2001-12-13 | — | — | US | disclosed |
| US-6258819-B1 | BIOLOGICAL RECEPTORS, ANTIINFLAMMATORY AGENTS, BENIGN PROSTATE AND SIDE EFFECT REDUCTION | SYNTEX (U.S.A.) LLC | 2001-07-10 | — | — | US | disclosed |
| WO-2001010860-A2 | QUINAZOLINONE AND AZAQUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-15 | — | — | WO | disclosed |
| EP-0464604-B1 | 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines | BRISTOL MYERS SQUIBB CO (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0345808-B1 | 1-Indolylalkyl-4-(substituted-pyridinyl)piperazines | BRISTOL MYERS SQUIBB CO (US) | 1995-01-11 | — | — | EP | disclosed |
| WO-1993014084-A2 | PIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
| EP-0464604-A2 | 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines | Bristol-Myers Squibb Company (US) | 1992-01-08 | — | — | EP | disclosed |
| US-5077293-A | Antidepressants | BRISTOL-MYERS SQUIBB CO. (US) | 1991-12-31 | — | — | US | disclosed |
| US-4954502-A | Antidepressants | BRISTOL-MYERS SQUIBB COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0345808-A1 | 1-Indolylalkyl-4-(substituted-pyridinyl)piperazines | Bristol-Myers Squibb Company (US) | 1989-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | CYP3A43, HMGCR, ABCG2 | MPO 4308/4885HTR2A 238/4885TRPM8 3545/4885 |
| US-20150056699-A1 | SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS | GFRA1, GFRA2, GFRA3 | MPO 1137/4885HTR2A 75/4885TRPM8 3291/4885 |
| US-20010051627-A1 | Substituted 2-(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)- 4(3H)-azaquinazolinones | ADRA2B, ADRA1D, ADRA1B | MPO 3869/4885HTR2A 126/4885TRPM8 1240/4885 |
| US-20130324579-A1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | MPO 1485/4885HTR2A 199/4885TRPM8 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.